| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Anti-Annexin V IgG and IgM
Test Code92977
CPT Codes
83516 (x2)
Preferred Specimen
0.5 mL serum collected in a red-top tube (no gel) or plasma collected in an EDTA (lavender-top) tube
Minimum Volume
0.2 mL
Transport Temperature
Frozen
Specimen Stability
Room temperature: 6 hours
Refrigerated: 5 days
Frozen: 6 months
Refrigerated: 5 days
Frozen: 6 months
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Received room temperature
Methodology
Enzyme Linked Immunosorbent Immunoassay (ELISA)
FDA Status
The performance characteristics of this test were determined by Pan Laboratories, Irvine, CA. It has not been cleared or approved by the U.S. Food and Drug Administration.
Setup Schedule
Sets up 1 day a week.
Report Available
2-7 days
Clinical Significance
Annexin V is a glycoprotein ( Mol Wt. 36 kD) that has the ability to bind to negatively charged phopholipids such as phosphotidyl serine with high affinity in a calcium- dependent manner. Based on its strong phospholipid binding activity, it inhibits in vitro the thrombinase complex and the tenase complex, resulting in potent anticoagulant activity. The occurrence of autoantibodies to annexin V has been described in several pathological disorders. It has been concluded that extracellular annexin V provides an antigenic stimulus for autoantibody production. The elevated levels of autoantibodies to annexin V (especially IgG isotype) have been demonstrated in serum samples of patients with systemic lupus erythomatosis(SLE), rheumatoid arthritis, recurrent fetal loss (miscarriage ) and pre-eclampsia. A number of studies suggest that the displacement of annexin V shield from the syncytiotrophoblast surface in the placenta by anti-annexin V antibodies is causative in the generation of a thrombogenic environment and consequently fetal loss. An increased prevalence of elevated anti-annexin V IgM, and to a lesser extent anti-annexin V IgG, was seen in recurrent spontaneous miscarriage patients.
